TPI Enterprises buys Vistin opiates assets and confirms Portugal plant plan

By Gareth Macdonald

- Last updated on GMT


Related tags Morphine

TPI Enterprises has bought Vistin Pharma ASA’s opiates and tabletting division for A$25.4m ($201.m) in a deal designed to expand the firm beyond its narcotic raw materials business.

The acquisition will see Melboure, Australia TPI take possession of a Vistin’s facility in Kragero, Norway. The site has capacity to make active pharmaceutical ingredients (API) – including codeine phosphate and pholcodine – as well is finished dosage forms.

TPI said buying the assets was part of its strategy of bolting “downstream” production capability to its existing narcotic raw material business to increase its profits.

The firm also said it plans to build an API manufacturing facility in Portugal, but declined to provide further information when contacted by

According to reports​ in the Portuguese press TPI has signed contracts worth €13m with poppy growers in the country in recent years.

Business expansion

TPI has been working to diversify its revenue since 2014​ when it announced its intention relocate its poppy straw processing operation in Cressy, Tasmania to a larger site on the Australian mainland.

Since then the firm has announced a number of major supply contracts. In August​ last year, it announced it had signed a deal worth $30m with an unnamed global pharmaceutical company.

In November​ TPI signed and manufacturing and supply deal with Sterling Pharma Solutions Ltd to manufacture and sell codeine phosphate in the UK.

Earlier this month TPI and Sterling signed a second supply contract. TPE said that both deals combined mean it will be supplying 20% of the 60 tonnes of codeine phosphate used in the UK each year.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more